Why Deprescribing Statins May Pose Risks for Older Adults

Close-up of a man's hands holding and pointing at white pills next to a prescription bottle.
Photo by Towfiqu barbhuiya on Pexels

Key takeaways

  • The STREAM trial investigated whether older adults without prior heart attacks or strokes could safely stop taking statin medications.
  • Although the study was technically classified as noninferior, the data showed that patients who stopped statins fared worse than those who continued.
  • Kaplan-Meier curves in the study diverged, indicating a growing difference in outcomes between the two groups over time.
  • The trial’s data safety monitoring board advised patients who have stopped statins to consult their doctors about resuming treatment.

Recent findings from the STREAM trial have sparked significant debate among preventive cardiologists regarding the safety and efficacy of deprescribing statins in older populations. While the study was designed to test if stopping these cholesterol-lowering drugs was a safe alternative for certain patients, the actual data presented at the American Heart Association’s recent annual meeting suggests a more complex and potentially risky reality.

For many years, the medical community has debated the necessity of long-term statin use in patients who have not yet experienced a major cardiovascular event. As patients age, the conversation often shifts toward “deprescribing”—the intentional process of reducing or stopping medications to minimize side effects and polypharmacy. However, the STREAM trial results indicate that for older adults without a history of heart attacks or strokes, the decision to stop statins may not be as neutral as researchers initially anticipated.

Spacious modern conference hall with wooden chairs and potted plants, perfect for
Photo by cottonbro studio on Pexels

What happened

At the American Heart Association’s annual meeting, researchers presented the results of the STREAM trial, a study focused on older adults who were currently taking statins but had no history of heart attacks or strokes. The goal of the trial was to determine if deprescribing statins would result in outcomes that were “noninferior” to continuing the medication.

In clinical research, a noninferiority trial is not trying to prove that a new intervention is better than the standard; rather, it seeks to prove that the new intervention is not significantly worse than the current standard. Based on the expectations set by the researchers at the beginning of the STREAM trial, the results were technically deemed noninferior.

However, Vishal Khetpal, a preventive cardiologist and assistant professor of medicine at the Northwestern University Feinberg School of Medicine, noted a troubling trend in the data. According to Khetpal, while the study met its technical statistical requirements for noninferiority, the visual representation of the data—the Kaplan-Meier curves—told a different story. Instead of the lines remaining close together, the curves diverged, showing that the group of patients who stopped taking their statins actually experienced worse outcomes compared to those who continued their medication.

Why it matters

This distinction between statistical noninferiority and clinical reality is critical for both physicians and patients. When a study is labeled “noninferior,” it means the difference between the two groups fell within a pre-specified, acceptable margin of error. But if that margin shows a consistent trend toward worse health outcomes, the clinical implications change entirely.

For the millions of older adults managing cholesterol through statins, the STREAM trial results suggest that stopping medication could lead to an increased risk of cardiovascular complications. The divergence in the Kaplan-Meier curves is a visual indicator that as time progressed, the cumulative risk for the group that underwent deprescribing increased more rapidly than for the group that remained on treatment.

This matters because the primary goal of statin therapy is the prevention of catastrophic events like myocardial infarctions (heart attacks) and strokes. If the act of stopping the medication leads to a measurable divergence in patient health, the practice of deprescribing becomes a high-stakes medical decision rather than a simple administrative adjustment to a patient’s pill load.

The science of noninferiority and clinical divergence

To understand why the STREAM trial is causing such confusion, one must understand the mechanics of how clinical trials are structured. In many modern medical studies, researchers use a “noninferiority margin.” This is a mathematically defined limit that represents the maximum amount of clinical difference researchers are willing to accept to say a new treatment is “not worse” than the old one.

Understanding the Kaplan-Meier Curve

In the context of the STREAM trial, the Kaplan-Meier curves are the primary tool used to track the probability of an event (such as a heart attack) occurring over a specific period.

  • Parallel Curves: If the curves for the group that continued statins and the group that stopped statins were parallel or overlapping, it would suggest that stopping the medication had no significant impact on health outcomes.
  • Diverging Curves: When the curves diverge, it means the gap between the two groups is widening over time. In the STREAM trial, the group that stopped statins saw their outcomes decline relative to the group that continued, creating a visible gap on the graph.

This divergence suggests that while the difference might not have been large enough to cross the strict statistical threshold of the noninferiority margin, the biological trend is clearly moving toward increased risk for those who stop the medication. This is why Khetpal described the findings as “puzzling.”

A doctor holds a pill bottle while consulting with an elderly patient.
Photo by Towfiqu barbhuiya on Pexels

Stakeholders and medical reactions

The findings have prompted immediate reactions from the medical community, particularly from those on the front lines of preventive cardiology.

The Data Safety Monitoring Board (DSMB):
One of the most significant signals from the trial came not from the primary researchers, but from the independent body responsible for patient safety. The trial’s data safety monitoring board suggested that patients who have stopped their statins should speak with their doctors about the possibility of resuming their medications. This is a rare and significant recommendation for a monitoring board to make during or immediately following a trial, as it directly counters the original intent of testing the safety of deprescribing.

Preventive Cardiologists:
Experts like Vishal Khetpal are calling for a more cautious approach to medication management in the elderly. The concern is that the drive to reduce polypharmacy—the use of multiple medications by a single patient—might be overshadowing the fundamental goal of cardiovascular protection. While reducing the number of pills can improve quality of life and reduce side effects, the STREAM trial suggests the trade-off might be a higher risk of serious cardiac events.

Patients and Caregivers:
For the aging population, the results introduce a new layer of complexity. Many seniors are advised to simplify their medication regimens to avoid drug-to-drug interactions or to manage the cost of prescriptions. However, the STREAM trial provides a cautionary note that simplification should never come at the expense of proven preventive measures without rigorous medical supervision.

What it means for you

If you are an older adult or a caregiver for an aging loved one, the results of the STREAM trial should inform how you approach cardiovascular health management.

If you are currently taking statins:

Do not stop your medication abruptly. The most important takeaway is that any decision to change your medication regimen must be made in consultation with a healthcare professional. The divergence in the STREAM trial suggests that stopping statins could lead to unexpected health risks.

If you are considering deprescribing:

Prepare specific questions for your doctor. If you or your physician are discussing the possibility of reducing your medication load, ask about the specific risks of your profile. You might ask:

  • “Based on my specific cardiovascular risk factors, what is the statistical likelihood of an event if I stop this medication?”
  • “Is my interest in stopping driven by side effects that can be managed in other ways?”
  • “How will we monitor my cholesterol and heart health if we decide to trial a period without statins?”

If you are a healthcare provider:

Re-evaluate the ‘neutrality’ of deprescribing. The STREAM trial serves as a reminder that ‘noninferior’ does not always mean ‘clinically equivalent.’ When reviewing a patient’s medication list, consider the visual and clinical trends in the data, not just the binary ‘pass/fail’ of a trial’s statistical threshold.

Counterpoints and open questions

Despite the concerns raised by the STREAM trial, there are valid arguments and complexities that prevent a one-size-fits-all conclusion.

The Argument for Deprescribing:
Proponents of deprescribing argue that for some very elderly patients, the benefits of statin therapy may be outweighed by the risks of side effects, such as muscle pain (myalgia), cognitive concerns, or the risk of falls due to dizziness. In patients with extremely limited life expectancy, the long-term preventive benefits of a statin may never materialize, making the reduction of pill burden a logical clinical move.

Unresolved Questions:
Several questions remain unanswered following the STREAM trial:

  1. Which specific subgroups are most at risk? The trial looked at older adults generally, but it is unclear if certain age brackets or those with specific co-morbidities are more susceptible to the risks of stopping statins.
  2. What was the magnitude of the divergence? While the curves diverged, the exact clinical significance of the increased risk needs further quantification in larger, more diverse cohorts.
  3. Can side effects be managed without stopping? Much of the push for deprescribing is driven by patient discomfort. Research into better-tolerated statins or lower-dose regimens remains a critical area of study.
A doctor uses a stethoscope for a patient's health check-up in a
Photo by Imad Clicks on Pexels

What happens next

The medical community will likely look toward follow-up studies to clarify the findings of the STREAM trial. Watch for the following developments:

  • Updated Clinical Guidelines: Major organizations like the American Heart Association (AHA) and the American College of Cardiology (ACC) may issue updated guidance on how to approach statin use in patients without established cardiovascular disease.
  • New Research on Side-Effect Management: As the debate continues, expect more research into how to mitigate the side effects that drive patients to want to stop their statins in the first place.
  • Refined Deprescribing Protocols: If the risks of stopping statins are confirmed to be significant, clinicians will need to develop more sophisticated, risk-stratified protocols for when deprescribing is truly appropriate and when it is dangerous.

The STREAM trial provides a vital, if complicating, piece of evidence in the ongoing conversation about cardiovascular prevention in aging populations. While the technical success of the trial’s noninferiority goal might suggest that deprescribing is a viable option, the diverging clinical data serves as a powerful warning that for many, the continued use of statins remains a critical component of heart health.”,
“meta_description”: “The STREAM trial results raise concerns about deprescribing statins in older adults

Frequently asked questions

What was the STREAM trial?

The STREAM trial was a clinical study designed to see if older adults who had not previously had a heart attack or stroke could safely stop taking their statin medications. The goal was to see if stopping the drugs (deprescribing) was “noninferior” to continuing them, meaning the results would not be significantly worse.

Why are doctors worried about the results?

Doctors are concerned because, although the study technically met its goal of being “noninferior,” the actual health data showed that the people who stopped taking statins actually fared worse over time. The visual data showed a growing gap in health outcomes between those who kept taking the medication and those who did not.

What does "noninferior" mean in a medical study?

In a noninferiority trial, researchers are not trying to prove a new treatment is better than the old one. Instead, they are trying to prove that the new treatment is not significantly worse than the current standard. In the STREAM trial, the group that stopped statins was technically within the acceptable margin of being “not worse,” but they still showed a trend toward poorer health.

Should I stop taking my statin if I am an older adult?

You should never stop taking a prescribed medication without talking to your doctor first. The STREAM trial results suggest that stopping statins could increase your risk of cardiovascular issues, and the trial’s own safety board recommended that patients consult their physicians about resuming treatment if they have stopped.

References

Featured image: Photo by Towfiqu barbhuiya on Pexels

Leave a Reply